Business Wire

Thermo King’s Truck Hybrid Refrigeration Units Hit the Roads

20.7.2020 07:30:00 EEST | Business Wire | Press release

Share

Thermo King®, a leader in transport temperature control solutions and a brand of Trane Technologies (NYSE: TT), today announced that its new hybrid refrigeration systems for trucks and high-loaders are being delivered to customers across Europe. The new T-Series Hybrid and UT Hybrid refrigeration systems seamlessly switch between diesel and electric mode allowing transporters to operate in inner cities, residential areas and low emission zones with the unit’s diesel engine turned off.

Greggs, UK’s leading bakery food-on-the-go retailer with over 1,800 shops nationwide and serving over six million customers a week, is one of the first customers in Europe to experience the benefits of the new hybrid refrigeration systems. Three new trucks with Thermo King’s hybrid systems will contribute to lowering the environmental impact and reducing operating costs of their truck transport operations in central London.

“Thermo King units have been our systems of choice for several years now. Their units have delivered good flexibility and work efficiency to our operations, and we could also always count on the Thermo King dealer service network to support us,” said Richard Penna, group logistics manager at Greggs. “We’re very cautious about the sustainability of our transport operations. It is paramount for us to operate in inner cities with as little noise and reduced emissions as possible. It was a natural choice to work with Thermo King and equip our trucks with these new units that can easily switch from diesel operation to electric, reduce the sound level and eliminate emissions. On top of that, we expect to benefit from the lower daily fuel consumption.”

“Thermo King Hybrid technology was designed to help transport and delivery companies future-proof their refrigerated operations and investments. With this solution they can stay ahead of regulations, control their total cost of ownership and achieve important sustainability goals,” said Colm O’Grady, product manager at Thermo King. “Thermo King was the first to offer its European customers a trailer hybrid refrigeration. Now, our truck transport customers can also benefit from this cleaner and electrified transport refrigeration to make urban distribution more flexible and sustainable.”

The new hybrid single- and multi-temperature solution for trucks feature Frigoblock alternator and inverter-drive technology. The nose-mount T-Series Hybrid and under-mount UT Hybrid refrigeration automatically switches between electric and diesel operation as required or necessary. This enables the transport companies to operate in inner cities, residential areas and low emission zones with the refrigeration unit’s diesel engine turned off.

The system is also well accepted by drivers, mainly due to the simple and smooth transition from one drive technology to the other. The driver only needs to set the vehicle when leaving the depot and the system will switch electric and diesel modes seamlessly during the working day depending on the unit’s requirements.

The T-Series Hybrid and UT Hybrid solutions are aligned with Trane Technologies’ 2030 sustainability commitments, and the commitment to reduce customers’ carbon emissions by one gigaton – equivalent to the annual emissions of Italy, France and the United Kingdom combined.

About Thermo King
Thermo King is a brand of Trane Technologies (NYSE: TT), a global climate innovator, and a worldwide leader in sustainable transport temperature control solutions. Thermo King has been providing transport temperature control solutions for a variety of applications, including trailers, truck bodies, buses, air, shipboard containers and railway cars since 1938. For more information, visit www.europe.thermoking.com or www.tranetechnologies.com.

About Trane Technologies
Trane Technologies is a global climate innovator. Through our strategic brands Trane® and Thermo King®, and our portfolio of environmentally responsible products and services, we bring efficient and sustainable climate solutions to buildings, homes and transportation. For more information, please visit tranetechnologies.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Geraldine Velner, Trane Technologies
+353-85-704-6944
Geraldine.velner@tranetechnologies.com

Investors:
Zachary Nagle, Trane Technologies
+1-704-990-3913
Zachary.nagle@tranetechnologies.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye